{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107304","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.984835+00:00","generated_at":"2026-05-17T14:46:48.457841+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026","bullets":["Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.","R&D expenses of $22.5M (down 20% YoY); G&A expenses of $7.0M (down from $8.6M).","MGX-001 hemophilia A program: IND/CTA submission planned in 2026; durable FVIII activity shown through 19 months in NHP study.","Appointed Laurence Reid, Ph.D., to Board of Directors in August 2025; established an R&D Committee.","Presented three abstracts at ASGCT on compact nucleases and CAST systems for targeted gene integration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107304","json":"https://secwatch.observer/filing/0000950170-25-107304.json","markdown":"https://secwatch.observer/filing/0000950170-25-107304.md","text":"https://secwatch.observer/filing/0000950170-25-107304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/0000950170-25-107304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/mgx-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:46:48.457841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}